MGX
Metagenomi Therapeutics
$1.21
+$0.00 (+0.41%)Jul 27, 2026
Key metrics
The numbers that frame MGX today
- Market cap
- $45.55M
- P/E (TTM)
- -0.5
- EV / FCF
- -0.6
- Gross margin
- 100%
- EV / Sales
- 2.5
- ROIC
- -40.6%
- Div yield
- 0%
- Debt / equity
- 0.3
- 52wk Low
- $1.13
- 52wk High
- $3.95
Growth
Revenue and earnings trend for MGX
RevenueNet income
See the full growth breakdown
Revenue and earnings trends, margins and the multi-year trajectory - free with an account.
Create a free accountFree foreverNo card required
Already a member? Log inCash flow & returns
Free cash flow and financial health
Free cash flowNet debt
See the full cash-flow picture
Free cash flow detail, returns on capital and the balance-sheet trend - free with an account.
Create a free accountFree foreverNo card required
Already a member? Log inInsider trading
Recent insider buying and selling activity
PurchasesSales
Unlock every insider trade
See who is buying and selling, how much, and when - updated as new filings land.
Create a free accountFree foreverNo card required
Already a member? Log inFrequently asked questions
Plain-English answers about MGX
Is Metagenomi Therapeutics a good buy?
No. Metagenomi Therapeutics has weak quality and poor momentum. Both signals point to a weaker setup. Growth looks mixed. The support signal is useful, but not decisive. We think Metagenomi Therapeutics is selling at a very high price.
What is the market capitalization of MGX?
Metagenomi Therapeutics's market capitalization is $45.55M.
What is the P/E ratio for MGX stock?
Metagenomi Therapeutics's current P/E ratio is -0.5.
What is the 52-week high for MGX stock?
The 52-week high for Metagenomi Therapeutics is $3.95. The current close of $1.21 is 69.4% below that high.
What is the 52-week low for MGX stock?
The 52-week low for Metagenomi Therapeutics is $1.13. The current close of $1.21 is 7.1% above that low.
Does MGX stock pay dividends?
Metagenomi Therapeutics does not currently show a dividend per share in the company data.
What is the Debt / Equity ratio for MGX?
Metagenomi Therapeutics's Debt / Equity ratio is 0.28.